6 20 24 FSHDUniversity Avidity Fortitude Update

In celebration of World FSHD Day 2024, join the Avidity Biosciences team as they share an update on the FORTITUDE™ study. The Avidity team, joined by Dr. Jeffrey Statland, University of Kansas Medical Center and FORTITUDE trial investigator, will present in-progress results from the FORTITUDE Phase 1/2 clinical trial evaluating AOC 1020 for adults with FSHD.
AOC 1020 is an antibody-oligonucleotide conjugate (AOCTM) being developed to target the root cause of FSHD. The primary goal of the FORTITUDE study is to evaluate the safety and tolerability of AOC 1020. Avidity designed FORTITUDE in partnership with patients, caregivers, advocates, and key physicians in the field to ensure the study best meets the needs of the FSHD community.
Avidity looks forward to recognizing World FSHD Day and welcoming you to the webinar.
#WorldFSHDDay #CureFSHD #Neuromuscular

[@braintic]

I've been waiting for 25 years for this. Hope this one makes it to market.

[@jorgeuriellopezcaballero2223]

I´ve been waiting for more than 35 years!

[@jorgeuriellopezcaballero2223]

I am very happy to be here! Grettings from México City

[@jorgeuriellopezcaballero2223]

Great News! Thanks for sharing… Doctor´s explanation very understandable and clear. All of you are making And amazing expanation of fhsd desease… I will share with those who tell me: the problem is in your mind so hurra up and move dońt be lazzy

[@megaman7551]

Exciting news! Can't wait to hear the results of the 4 mg/kg part b study. Also they didn't mention anything about the mri results ( guess it's only been 4month so probably wouldn't show much)